1. A method for the treatment of epilepsy syndrome and/or seizure in a subject,
comprising administering a therapeutically effective amount of a compound, or
salt thereof, of Formula I
5
Formula I
wherein A, B, C, X, Y, and Z are independently selected from H or OH
groups.
2. The method as claimed in claim 1, wherein said compound is at least one
10 selected from the group consisting of
urolithin A, urolithin B, urolithin C, urolithin D and urolithin E.
3. The method as claimed in claim 1, wherein said salt is a salt of an acid
selected from hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid,
phosphoric acid and the like, acetic acid, trifluoroacetic acid, propionic acid,
15 glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid,
fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic
acid, methane sulfonic acid, ethane sulfonic acid, p-toluene sulfonic acid,
salicylic acid, or combination thereof.
4. The method as claimed in claim 1, wherein said salt is selected from sodium
20 salt, potassium salt, lithium salt, ammonium salt, calcium salt, magnesium salt,
iron salt, zinc salt, copper salt, manganese salt, aluminium salt, or combination
thereof.
21
5. The method as claimed in claim 1, wherein said epilepsy syndrome is
selected from Dravet syndrome, idiopathic generalised epilepsy, juvenile
absence epilepsy, juvenile myoclonic epilepsy, Landau Kleffner syndrome,
Lennox Gastaut syndrome, myoclonic astatic epilepsy, childhood absence
5 epilepsy, west syndrome, Panayiotopoulos syndrome, benign rolandic epilepsy,
refractory epilepsy, or childhood idiopathic occipital epilepsy.
6. The method as claimed in claim 1, wherein said seizure is selected from
simple focal seizure, complex focal seizure, secondary generalized seizure,
absence seizure, or tonic clonic seizure.
10 7. The method as claimed in claim 1, wherein the therapeutically effective
amount of the compound is in the range of 4 to 25 mg/kg.
8. A compound, or salts thereof, of Formula I
Formula I
wherein A, B, C, X, Y, and Z are independently selected from H or OH groups, for
15 use in the treatment of epilepsy syndrome and/or seizure in a subject.
9. The compound as claimed in claim 8, wherein said compound is at least one
selected from the group consisting of
urolithin A, urolithin B, urolithin C, urolithin D and urolithin E.
10. The compound as claimed in claim 8, for use in the preparation of a
20 medicament for the treatment of epilepsy syndrome and/or seizure in a subject.